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Eric J. Topol, MD; Patrick W. Serruys, MD, PhD
In more than 20 years since the first percutaneous coronaryrevascularization procedures, the field of interventional
cardiology has proliferated beyond all expectations. Now
more than 1 million procedures are performed worldwide
each year. Stenting has revolutionized the field, which pre-
viously relied on balloon dilatation in the majority of patients.
With '50% of patients now undergoing stent implantation,
the groundwork is laid for further important advances. In this
article, we discuss the 4 most important new advances in the
field of interventional cardiology: platelet inhibition, preven-
tion of restenosis, stent evolution, and angiogenesis.
Platelets
Proximate Cause of Stent Thrombosis
Considerable progress in the field of percutaneous coronary
revascularization has been made by appreciation of the
pivotal role of platelets and the development of new therapies
directed against platelet aggregation. The entire field of
stenting was catapulted forward with the realization that
subacute thrombosis was predominantly attributable to a
platelet thrombus. Since the beginning of coronary stenting in
1986, thromboprophylaxis consisted of full doses of heparin
and coumarin, along with aspirin and dipyridamole.1,2 This
regimen resulted in the necessity for prolonged hospital stays
to achieve therapeutic anticoagulation and in excessive bleed-
ing complications and was still ineffective in preventing stent
thrombosis in at least 4% to 5% of patients.2–6 The prevailing
belief was that stent thrombosis, which occurred primarily
several days after the index procedure, was due to a fibrin-
rich (red) thrombus.7–9 Many of the cases of stent thrombosis
were linked to suboptimal anticoagulation.8,9 The complica-
tion of stent thrombosis is dreaded, because it may result in
myocardial infarction (MI) or death.10 The possibility that
stent thrombosis was precipitated by inadequate expansion of
the stent was explored11,12 independently of the search for a
better pharmacological protective strategy.
Evidence for causal white thrombus came from platelet
flow cytometry data, indicating the increased expression of
the platelet glycoprotein IIb/IIIa receptor in patients who
developed this complication of stenting.13 Rather than abnor-
malities in markers of coagulation activation, such as the
cleaved fragment of prothrombin (F1.2) or thrombin-
antithrombin complexes, a series of consecutive patients
demonstrated that the dominant biochemical abnormality was
related to platelet activation.
Angioscopic data from patients with subacute stent throm-
bosis showed white (platelet-rich) thrombus as the culprit,14
and reports of failure of plasminogen activators to achieve
lysis of stent thrombosis15 corroborated the sense that the
pathogenesis of this entity was largely attributable to platelet
aggregation. Clinical trials were mounted to test the value of
a platelet-directed strategy of aspirin and ticlopidine com-
pared with the full anticoagulation approach of prolonged
heparin and coumarin.16,17 Furthermore, trials compared aspi-
rin as a sole antiplatelet agent with the combination of aspirin
and the ADP receptor antagonist ticlopidine.17–20 These trials
are summarized in Table 1. The benefit of an antiplatelet
approach over the traditional strategy was striking, as first
shown in the Munich Intracoronary Stenting and Antithrom-
botic Regimen (ISAR) trial and later confirmed in the Stent
Anticoagulation Regimen Study (STARS) trial.16,17 These
findings, coupled with the benefit of an intensified dual
antiplatelet inhibitor approach as opposed to aspirin alone,17–20
provide a very strong foundation for platelet thrombus to be
regarded as the principal pathogenic factor in stent thrombo-
sis. The incidence of subacute stent thrombosis is now
regarded as ,1% to 2%. Accounting for this are the 2
cardinal changes in approach: more optimal deployment by
use of higher balloon dilatation pressures, and combination
antiplatelet therapy with aspirin and ticlopidine. The marked
reduction in the incidence of stent thrombosis and the
simplification of the pharmacological regimen has greatly
reduced the cost of stenting by making overnight hospital
stays routine, along with the possibility of transforming stent
deployment to an outpatient procedure in select patients.21
Recently, ticlopidine has been associated with thrombocy-
topenic thrombotic purpura.22,23 A new ADP receptor antag-
onist, clopidogrel, has thus far not been shown to induce this
serious microangiopathic disorder or been implicated in bone
marrow toxicity. Clopidogrel is currently being assessed in
coronary stent trials for comparative efficacy and safety
compared with ticlopidine.
Development of IIb/IIIa Inhibitors
Parallel to the improvement in pharmacological coverage to
protect against stent thrombosis, a new class of drugs was
being explored for balloon PTCA. For several years, it had
been known that a final common pathway for platelet
aggregation existed. Elucidation of the biology of this glyco-
protein IIb/IIIa receptor, the most densely expressed adhesion
molecule on the platelet surface, laid the groundwork for
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Coller24 to develop a monoclonal antibody.25 The antibody
was the first agent to enter clinical trials, later followed by a
peptide and several small-molecule competitive inhibitors of
this adhesion molecule receptor.
Six large placebo-controlled, double-blind trials were un-
dertaken to test IIb/IIIa antagonists in patients undergoing
PTCA, as summarized in Table 2.26–31 The Evaluation of
IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ische-
mic Complications (EPIC) trial26 was the first “proof of
concept” and demonstrated a marked, 36% reduction in the
incidence of death or MI within 30 days of the procedure
(Figure 1). This trial was conducted in high-risk patients,
eligible because of an acute coronary syndrome or known
angiographic liabilities for acute complications.25 Either
PTCA or directional atherectomy was the revascularization
procedure. Of note, only the bolus and sustained infusion
(.12 hours) but not the bolus per se strategy was effective in
reducing adverse outcomes. This strongly suggested that the
duration of IIb/IIIa blockade would play out as an important
modulator of therapeutic potential.
The subsequent 5 trials confirmed and extended the EPIC
findings in many ways.27–31 First, each trial showed benefit of
IIb/IIIa inhibition (Figure 1), with reduction of major adverse
events. Second, the field of patients was expanded to include
any routine percutaneous intervention rather than only a
high-risk inclusion criterion. Third, the bleeding complica-
tions encountered in EPIC were related to excessive heparin
and prolonged indwelling vascular sheath time. In the trials
that followed, using lower doses of weight-adjusted heparin
and reducing the time of vascular sheaths, the initial doubling
of bleeding in the patients receiving IIb/IIIa was reduced to
levels similar to those in the control group.30
Stents and IIb/IIIa Inhibitors
By virtue of the benefit of 2 different and distinct mecha-
nisms, the concept of using both arterial scaffolding and
protection from platelet thrombosis represents an attractive
clinical strategy. Supportive data for this combination in
patients receiving stents were demonstrated in subgroups of
randomized trials.32,33 As shown in Figure 2, in the Evaluation
of PTCA to Improve Long-term Outcome by c7E3 GPIIb/IIIa
Receptor Blockade (EPILOG) trial, .300 patients underwent
stenting because of suboptimal balloon angioplasty results,
and the benefit for IIb/IIIa inhibition with respect to reduction
of MI and emergency revascularization was striking.32 Of
note, the favorable effects for combined IIb/IIIa inhibition
TABLE 1. Stent Randomized Thromboprophylaxis Trials
Composite Event Rates (Death, MI,
Revascularization), %
Trial n ASA1Ticlid ASA only ASA1Coumarin
Hall et al18 226 0.8 3.9 z z z
ISAR16 517 1.6 z z z 6.2
FANTASTIC19 485 5.7 z z z 8.6
STARS17 1652 0.6 3.6 2.4
MATTIS20 350 5.6 z z z 11.0
ASA indicates aspirin; ISAR, Intracoronary Stenting and Antithrombotic
Regimen trial; FANTASTIC, Full ANticoagulation versus Ticlopidine and Aspirin
after STent Implantation: a randomized multiCenter European study; STARS,
Stent Anticoagulation Regimen Study; and MATTIS, Multicenter Aspirin and
Ticlopidine Trial after Intracoronary Stenting in high-risk patients.
TABLE 2. Principal Features of the 6 Large Trials of IIb/IIIa Inhibitors in Interventional Cardiology
Trial n Drug Patients Heparin Sheath Time, h
EPIC 2099 Abciximab High-risk Full .24
IMPACT 4010 Eptifibatide No restriction* 100 U/kg, weight adjusted '6
RESTORE 2139 Tirofiban Unstable angina, acute MI Full '6
CAPTURE 1265 Abciximab Unstable angina Full .24
EPILOG 2792 Abciximab No restriction* 70 or 100 U/kg, weight adjusted ,6
EPISTENT 2399 Abciximab No restriction* 70 or 100 U/kg, weight adjusted ,6
EPIC indicates Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications; IMPACT, Integrelin to
Manage Platelet Aggregation to prevent Coronary Thrombosis; RESTORE, Randomized Efficacy Study of Tirofiban for Outcomes and
Restenosis; CAPTURE, Chimeric 7E3 Anti-platelet in Unstable angina Refractory to standard treatment; EPILOG, Evaluation of PTCA to
Improve Long-term Outcome by c7E3 GPIIB/IIIa receptor blockade; and EPISTENT, Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
*No restriction refers to enrollment of all patients suitable for percutaneous intervention using a Food and Drug Administration–
approved device. Rotablation as a planned revascularization was not an entry criterion in EPILOG.
Figure 1. Death or nonfatal MI at 30 days for 5 trials of IIb/IIIa
inhibitors in interventional cardiology procedures. EPIC indicates
Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Prevent-
ing Ischemic Complications; IMPACT, Integrilin to Manage
Platelet Aggregation to prevent Coronary Thrombosis;
RESTORE, Randomized Efficacy Study of Tirofiban for Out-
comes and Restenosis; CAPTURE, Chimeric 7E3 Anti-Platelet in
Unstable angina Refractory to standard treatment; EPILOG,
Evaluation of PTCA to Improve Long-term Outcome by c7E3
GPIIb/IIIa receptor blockade; and EPISTENT, Evaluation of
Platelet IIb/IIIa Inhibitor for Stenting.
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(administered on a prophylactic basis) and stenting had thus
far been shown only in patients with poor or suboptimal
initial results. A dedicated trial (known as Evaluation of
Platelet IIb/IIIa Inhibitor for Stenting [EPISTENT]) studied
the use of IIb/IIIa blockade with elective stenting.31 In this
trial, balloon angioplasty and abciximab was compared with
either stenting and placebo or stenting and abciximab in a
total of 2399 patients. For the combination of stenting and
abciximab, compared with stenting and placebo, a striking
(.50%) reduction of death and MI at 30 days and 6 months
was demonstrated.31 The balloon-abciximab arm also was
significantly improved compared with stenting and placebo.31
These findings accentuate the need for improved antiplatelet
therapy with percutaneous intervention, whether it be with
stenting or balloon angioplasty.
The IIb/IIIa trials in interventional cardiology, interest-
ingly, have consistently reduced the need for emergency or
“bailout” stenting33,34 (Figure 3). Each trial that was per-
formed in an era in which stents were available showed a
lesser need, with an overall 24% reduction. All of these trials
were performed in a double-blind fashion. This, along with
the consistent findings across trials and the magnitude of the
reduction, bespeaks a prominent effect of improved antiplate-
let coverage for achieving better results in percutaneous
intervention without stenting. Whether indeed stenting should
be avoided when possible or actually applied more frequently
is an unsettled issue.35 Notwithstanding the provisional stent
debate, the interaction of stenting and antiplatelet therapy is
clearly a critical one for future optimization of patient
outcomes.
Restenosis
Initially, it was thought that IIb/IIIa blockade might have a
salutary effect on clinical restenosis.36 This was based on the
long-term effects of the original EPIC trial, in which there
was a 24% reduction of target-vessel revascularization at 6
months in the abciximab bolus and infusion treatment
group.36 Furthermore, this benefit was sustained even at 3
years of follow-up.37 Theoretically, this occurred on the basis
of potent platelet inhibition before and for the first few days
after the arterial dilatation. By attenuation of the platelet-
aggregation response, less growth factor (such as platelet-
derived growth factor) and vasoactive amine (eg, serotonin,
thromboxane A2) would be released. In addition, abciximab is
known to inhibit the vitronectin receptor, an integrin with
homology to IIb/IIIa because of the shared b-3 subunit and
.70% of the a-subunit. Because abciximab cross-reacts fully
with the vitronectin receptor38,39 and this is a critical pathway
for governing smooth muscle cell migration, theoretically a
dual approach of platelet and smooth muscle cell antagonism
was operational. However, when the same IIb/IIIa inhibitor
was used in the subsequent EPILOG trial, there was no
6-month effect on target-vessel revascularization.30 This was
also the case in both the ERASER and RAPPORT trials,40,41
as summarized in Table 3.
As shown in Figure 4, however, there was a pronounced
change in the need for target-vessel revascularization from
the initial to the more contemporary abciximab trial. This
reduction in the placebo group of the respective trials is quite
impressive and probably reflects the era of more aggressive
dilatation that has characterized percutaneous intervention
since backup stenting was widely available in 1995. More
recently, however, data from the EPISTENT 6 month
follow-up results have become available. An overall 18%
reduction in the need for repeat target vessel revascularization
was demonstrated for abciximab compared with placebo in
stent assigned patients (from 10.6% to 8.7%) with .50%
reduction in diabetic patients (16.6% vs 8.1%, P50.02).
Thus, in-stent restenosis, especially in diabetics, is favorably
influenced by abciximab.31
Periprocedural MI
Since the first randomized trial of directional atherectomy
versus balloon angioplasty,42 debate has arisen as to the
significance of periprocedural non–Q-wave MI, which clearly
occurs more frequently than expected. In aggregate, a number
of studies with ample follow-up have shown that patients
with a periprocedural MI characterized by a 3-fold elevation
of total creatine kinase (CK), positive for myocardial band
(MB), have a compromised long-term prognosis.43 The pa-
Figure 2. Reduction of death, MI, or need for urgent revascular-
ization in prophylactic abciximab arm of a subgroup of 322
patients in EPILOG who underwent stenting for suboptimal
results.
Figure 3. Need for stenting for bailout or suboptimal results in
double-blind, placebo-controlled trials of IIb/IIIa inhibitors for
interventional cardiology. RAPPORT indicates Reo Pro and Pri-
mary PTCA Organization and Randomized Trial; other abbrevia-
tions as in Figure 1.
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tients most apt to have a periprocedural non–Q-wave MI are
those with diffuse atherosclerotic involvement, with long
lesions or saphenous vein graft target stenoses, along with
procedures that induce a deeper level of arterial injury,
particularly atherectomy.44,45 Common to these higher-risk
subsets is the responsiveness of IIb/IIIa inhibitors for the
reduction of periprocedural MI. Although the predominant
therapeutic effect of the IIb/IIIa inhibitors is in large MIs,
Q-wave or non–Q-wave, there is clear-cut reduction of
periprocedural MIs in the range of 3- to 5-fold CK eleva-
tion.26–31 Accordingly, using this drug class as a mechanistic
probe, we know that at least some of these events are
attributable to platelet aggregation, whether it be the site of
arterial dilatation or in the microcirculation. The weight of
evidence suggests that the chief hazard of periprocedural MI
is increased death rate during extended follow-up,43 which
appears to be directly related to the size of the MI. This may
explain the favorable impact of IIb/IIIa blockade on mortality
during 3-year follow-up of a cohort of patients with acute
coronary syndromes in the initial EPIC trial.37 Nevertheless,
periprocedural MIs still occur despite full doses of IIb/IIIa
inhibitors, so that other factors, such as side-branch closure,
atherosclerotic emboli, and overriding intimal disruption,
play a role in some patients.
Use in Acute MI
One of the most exciting frontiers in cardiovascular medicine
is the ability to disaggregate platelets in the setting of acute
MI.46 The underlying pathophysiology has been further elu-
cidated, with the white clot central to the response to plaque
fissure or erosion and the attendant exposure of subendothe-
lial matrix. Until recently, there was no tool in our therapeutic
armamentarium to dissolve the platelet clot—that is, to
achieve “platelet lysis.” Indeed, the prothrombotic effects of
plasminogen activators led to failure of angioplasty in the
early randomized trials.46–49 This has been completely turned
around by exploiting our newfound ability to dissolve white
clot in the acute setting, with or without fibrinolytic therapy.
Use of IIb/IIIa inhibition alone has resulted in infarct vessel
patency rates approximating the use of streptokinase
therapy.50
In the recently completed RAPPORT trial,41 of 483 patients
undergoing PTCA for acute MI, the IIb/IIIa inhibitor group
had a .40% reduction in death, MI, or urgent revasculariza-
tion at 30 days (Figure 5). Neumann and colleagues,51 from
Munich, Germany, reported a trial of 200 patients undergoing
primary stenting for acute MI with a similar reduction of
adverse outcomes with abciximab compared with conven-
tional pharmacological therapy. Recent data from dose-
finding trials in the TIMI-14 and GUSTO-4 trials indicate
TABLE 3. Major 6-Month End Points of the 5 Trials of IIb/IIIa Blockade in
Interventional Cardiology
% Death/MI % Death/MI/Any Revasc % TVR
Trial n Placebo Drug Placebo Drug Placebo Drug
EPIC 2099 12.8 8.8 35.1 27.0 22.3 16.5*
IMPACT 4010 11.6 10.3 31.5 30.1 20.7 20.9
RESTORE 2139 8.6 7.8 27.1 24.1 17.1 15.7
CAPTURE 1265 10.9 9.0 31.6 31.4 25.9 25.8
EPILOG 2792 11.1 6.0 25.8 22.5 18.1 16.6
Pooled 12 305 10.9 8.5 29.8 26.9 20.2 18.6
TVR indicates target vessel revascularization; EPIC, Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in
Preventing Ischemic Complications; IMPACT, Integrelin to Manage Platelet Aggregation to prevent Coronary
Thrombosis; RESTORE, Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis; CAPTURE, Chimeric 7E3
Anti-platelet in Unstable angina Refractory to standard treatment; and EPILOG, Evaluation of PTCA to Improve
Long-term Outcome by c7E3 GPIIb/IIIa receptor blockade.
Figure 4. Proportion of patients requiring repeat target-vessel
revascularization in control groups of EPIC trial (conducted in
1992; control group, n5639) vs EPILOG trial (conducted primar-
ily in 1995; control group, n5939) shows marked reduction in
more contemporary trial (TVR required in 22.3% in EPIC, 16.6%
in EPILOG).
Figure 5. RAPPORT trial event rates of death, MI, and urgent
revascularization for abciximab vs placebo.
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that half-dosing of tissue plasminogen activator (alteplase) or
recombinant tissue plasminogen activator (reteplase), respec-
tively, given in combination with full-dose abciximab, can
achieve infarct vessel patency in .90% of patients by 60 to
90 minutes into therapy.52,53 In the related trials of acute
coronary syndromes, the patients receiving IIb/IIIa blockers
on presentation who had subsequent percutaneous coronary
intervention during drug infusion derived the most benefit of
all of the subgroups analyzed (Table 4).54–56
It is thus likely that a pivotal component of future man-
agement of MI patients will involve more potent antiplatelet
therapy. The long-standing debate as to whether to perform
catheter-based reperfusion or use pharmacological therapy
could be preempted by a pharmacological strategy that
markedly facilitates (rather than compromises) acute-phase
intervention. Because one of the most important features of
acute intervention is the “door-to-balloon” time,57,58 the use of
a platelet-lysis approach to restore coronary blood flow while
the patient is being transported to cardiac catheterization has
important infarct-size limitation and practical appeal. Further-
more, the enhanced stability of the infarct vessel that has been
passivated by the use IIb/IIIa blockade opens the potential for
consideration of very early hospital discharge. Thus, IIb/IIIa
blockade has set the stage for a veritable revolution in our
care of the patient with acute MI eligible for reperfusion
therapy.
Antirestenosis Strategies
The focus of the treatment of restenosis over the last 2
decades has been through the application of pharmacologi-
cally active agents and mechanical approaches using a host of
different devices. Unfortunately, this frequent and costly
complication of percutaneous revascularization techniques
has proved refractory to all such therapies. The restenosis
process is characterized by neointimal proliferation, which
involves the migration of vascular smooth muscle cells from
the media to the intima and their subsequent proliferation.
The inciting stimuli involved in restenosis include disruption
of the endothelial barrier layer, mechanical factors that
disrupt the medial smooth muscle layer and serve as stimuli
for smooth muscle cell proliferation and migration, and the
contact of this disrupted layer with circulating blood factors
and mitogens that serve as further stimuli to neointimal
formation. Vascular injury sets into motion a cascade of
events that results in the final hyperplastic response shown by
the neointima. Early in our understanding of the pathophys-
iological processes involved in restenosis, attention was
concentrated on factors that interact with smooth muscle cells
through cell surface receptors. These include such com-
pounds as thrombin, platelet-derived growth factor, angioten-
sin II, interleukin 1, insulin growth factor-l, basic fibroblast
growth factor, and a whole host of other mitogenic factors.
Initial treatments for restenosis targeted these receptors with
pharmacological agents in an attempt to inhibit their effects.
It soon became apparent, however, that none of these stimuli
work through a unique or final common pathway. Instead,
these signals interact at an intracellular level through redun-
dant second-messenger systems, which confers redundancy to
the system. Ultimately, these second-messenger systems con-
verge on a final common pathway at the cellular DNA level
known as the cell cycle.
The life cycle of a normal cell can be considered in 5
different cell phases. G0 (G5gap) is the quiescent state in
which the cell is biologically active but is neither actively
dividing or replicating. Under appropriate stimuli, the cell can
then enter the G1, or interphase, in which biosynthetic
activities of the cell prepare it to enter into the next phase of
the cell cycle, or S phase. The S phase begins when DNA
synthesis starts and ends when the DNA content of the
nucleus has doubled and the chromosomes have replicated.
The S phase is followed by G2, which ends when mitosis
starts, signaling the start of the M phase. Activation of the cell
cycle is responsible for both normal physiological growth and
cell division, as well as for pathophysiological processes such
as restenosis.
A large number of genes are involved in the control of cell
cycle progression in eukaryotic cells. They can be divided
into early G1 genes (such as c-fos c-myc, etc), late G1 genes
(c-myb, Rb, etc), genes involved in G1/S transition (cdc/ckd
kinases, etc), S-phase genes involved in DNA synthesis
(DNA polymerases, proliferating cell nuclear antigen, etc),
genes involved in G2/M transition (cdc/ckd kinases, etc), and
genes involved in mitosis (cytoskeletal proteins, mitosis-
specific kinases, etc). In theory, suppression of any 1 of these
genes will lead to interruption of cell cycle progression, a
strategy that is being explored for the prevention of restenosis
as we approach the new millennium. Two different tactics are
currently being tested. Brachytherapy bombards the nuclear
material with ionizing radiation, disrupting the templates for
the production of cell cycle regulatory proteins. With the
correct radiation dose, the target smooth muscle cell remains
TABLE 4. Use of Percutaneous Coronary Revascularization While on IIb/IIIa Blockade Therapy
in 3 Trials of Empirical Therapy in Acute Coronary Syndromes
Proportion (%) of Patients
Undergoing
30-Day Death/MI Event
Rates, %
Angiography PTCA Placebo IIb /IIIa
Absolute Reduction in
PTCA Patients, %
PARAGON A 10.8 3.2 15.2 2.6 12.6
PRISM Plus 89.7 30.5 14.4 8.4 6.0
PURSUIT 79.0 34.0 16.8 11.5 5.3
PARAGON A indicates Platelet IIb /IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global
Organization Network; PRISM Plus, Platelet Receptor inhibition for Ischemic Syndrome Management study; and
PURSUIT, Platelet IIb /IIIa Underpinning the Receptor for Suppression of Unstable Ischemia Trial.
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viable but unable to replicate. The other approach depends on
a biological attack on the cell regulatory machinery using
gene therapy technology for the introduction of foreign-
fragment nuclear material to halt the pathophysiological
processes typical of restenosis.
A number of different approaches using the basic tech-
niques of gene therapy are currently being tested for the
prevention of neointimal hyperplasia. The most straightfor-
ward involve the transfer of a gene directly into the prolifer-
ating smooth muscle cells. This gene can encode for a
cytotoxic protein (eg, herpes virus thymidine kinase), a cell
cycle–inhibitory protein (eg, p53, p21, Rb, cdk), angiogenic
proteins (eg, vascular endothelial growth factor [VEGF],
angiogenin, basic fibroblast growth factor), or proteins with
vasodilatory, antithrombotic, or antiproliferative properties
(eg, nitric oxide synthase, cox-l, plasminogen activator inhib-
itor type 1). This kind of approach has been shown to be
effective in several animal models of restenosis. With adeno-
virus used as a vector, herpes virus thymidine kinase has been
successfully transfected into vascular smooth muscle cells at
the site of balloon injury in the femoral arteries of swine.59
This was followed by systemic administration of the nucle-
oside analogue ganciclovir, which in the presence of the
foreign thymidine kinase can be incorporated into the cellular
DNA. With this technique, both smooth muscle cell prolifer-
ation and luminal narrowing were shown to be inhibited.59
Adenovirus-mediated transfer of the retinoblastoma (Rb)
gene, whose protein product inhibits cell cycle progression,
has also been shown to be successful in a similar animal
model.60 Transfer of the gene coding for nitric oxide synthase
using both a protein/liposome hybrid vector61 and an adeno-
virus vector,62 as well as of angiotensin II type 2 receptor63
and the thrombin inhibitor hirudin64 using adenovirus vectors,
has also been shown to be effective for the prevention of
restenosis in the rat carotid model of vessel injury.
Other targets being investigated for the prevention of
restenosis are the matrix metalloproteinases (MMPs). Smooth
muscle cell migration and proliferation are normally hindered
by the inhibitory constraints of the extracellular matrix.65,66
Matrix remodeling by matrix-degrading metalloproteinases is
therefore essential for smooth muscle proliferation and mi-
gration into the intima. Synthetic inhibitors of MMPs have
been shown to inhibit smooth muscle migration and prolifer-
ation in several in vitro systems.66–70 There are several
naturally occurring tissue inhibitors of metalloproteinases
(TIMPs) that can inhibit their activity. To date, 3 TIMPs have
been well characterized (TIMP-1, -2, and -3),71 and a fourth
has been cloned.72 The identification of these inhibitors has
led to the idea that overexpression of TIMPs may have
potential as a gene therapy approach for the prevention of
neointimal formation. Support for TIMP gene therapy comes
from recent work by George and colleagues73 at the Bristol
Heart Institute. In human saphenous vein in tissue culture,
these investigators were able to demonstrate that highly
localized overexpression of TIMP-1 after recombinant
adenovirus-mediated transfection markedly inhibited neointi-
mal formation. These results not only provide proof of
principle for ex vivo gene therapy with TIMP-1 for the
reduction of neointimal formation in vein grafts but also
suggest an in vivo application at the time of intervention for
the prevention of coronary artery restenosis.
Another “nuclear weapon” being developed for the preven-
tion of restenosis involves antisense oligonucleotide technol-
ogy. Antisense oligodeoxynucleotides are short pieces of
DNA with sequences that are complementary to specific
regions of messenger RNA. The major mechanisms of action
of these compounds are through the sequence-specific inter-
action with messenger RNA, although sequence-specific and
sequence-nonspecific effects have also been demonstrated.
On binding to the target, the antisense compound sterically
inhibits the interaction of ribosomes with the messenger
RNA. Another mechanism of action, which may be as
important as the steric inhibition of ribosome binding, is a
consequence of the DNA/RNA hybrid being more susceptible
to degradation by intracellular RNAse than single-stranded
messenger RNA. This results in an increased clearance of
target mRNA from the cell. In principle, any gene may be
selected for antisense suppression; inhibition of certain genes
will certainly be more biologically effective. Important in this
regard are the abundance of the messenger RNA, the half-life
of the protein product, and the existence of redundancy within
the cell such that other proteins are capable of performing
functions similar to that which is targeted. Given these
considerations, it is not surprising that most of the attention of
antisense technology has been focused on the short-lived
regulators of the final common pathway of mitogenic stimuli,
the cell cycle. Inhibition of the production of several of the
mediators of the cell cycle with antisense oligonucleotides
has been shown to be effective for the prevention of resteno-
sis in several different animal models of vascular injury
(Table 5).74–84 The results of a single-center clinical trial
performed in Rotterdam that examined the effectiveness of
antisense compound directed against messenger RNA for the
protein product of the c-myc gene will soon be reported. This
will be the first human trial to use an antisense DNA strategy
for the prevention of restenosis.
With our increased understanding of vascular molecular
biology, more sophisticated approaches that use the basics of
gene therapy are being investigated. For instance, cell-based
vascular gene-delivery techniques are now being explored as
means to provide biologically relevant amounts of therapeutic
agents to the site of vessel damage. This strategy involves the
isolation of autologous endothelial or smooth muscle cells, ex
vivo gene transfer, followed by the reintroduction of the
genetically modified cells back to the region selected for
therapy. The disadvantages of this approach include the
requirement to isolate and modify cells from each patient,
with the consequent delay in therapy, and the failure to date,
with few exceptions, to show a relevant expression of
recombinant protein in vivo. To circumvent these problems,
the laboratory of one of the authors (P.W.S.) is focusing on
the xenotransplantation of genetically modified endothelial
cells for the prevention of restenosis. For this purpose,
animals have been engineered that are doubly transgenic in
that they carry not only a human gene that can produce an
agent for the prevention of restenosis but also gene coding for
human cell surface markers so that they may be effectively
xenotransplanted into humans and therefore provide a local
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source of bioactive compounds. These animals provide a
limitless supply of endothelial cells producing controllable
levels of active compound, which can be used for xenotrans-
plantation at the site of vessel injury in humans. These foreign
cells act as a kind of Trojan horse, graciously accepted as self
by the host organism but capable of modifying the pathophys-
iological response to vessel damage typified by the process of
restenosis. Once implanted, the production of the bioactive
compound is under exogenous control by means of “design-
er” genes coding for modified cell-surface receptors that are
introduced. In this system, interaction of an orally adminis-
tered compound with the modified cell receptor can switch on
the transgene, whereas in its absence the transgene remains
dormant. The feasibility of this type of approach has been
demonstrated in other animal species, and it shows great
potential for application to humans. The applicability of this
type of therapeutic delivery system to other pathophysiolog-
ical conditions and the shortage of tissue for organ transplan-
tation are the fuel for continued high research activity in this
direction.
As our understanding of the molecular control of cellular
function increases and our knowledge of the pathophysiology
of restenosis expands, new types of gene therapy approaches
will be developed for the treatment of this iatrogenic com-
plication. An area of active investigation is the development
of new techniques for the introduction of foreign DNA into
whole cells. All of the currently available viral and nonviral
vectors have significant limitations to their use. The intro-
duction of an effective, nonimmunogenic delivery vehicle is
on the horizon. As the last decade was the era of mechanical
and pharmacological approaches to the prevention of reste-
nosis, developments in the coming decade will be aimed at
manipulating the genetic material of the proliferating cell.
Stents
The use of coronary stent implantation as a primary treatment
modality in interventional cardiology has increased at a
staggering rate. In most interventional centers, stents are used
in $50% of all coronary angioplasty procedures. This “sten-
tomania” is driven both by the gratifying short-term results
seen by the interventionalist using these devices and by
results extrapolated from observational and randomized trials.
The “bigger is better” dogma first proposed by Kuntz and his
colleagues85 has been adopted by many operators, who feel
that the greater the acute gain in lumen diameter, the smaller
the chances of short- and long-term failure.86 Inherent in this
concept is that the stent is merely a means to an end, and
therefore, irrespective of the particular stent or other dilating
or debulking device used, success of the procedure is deter-
mined solely by the acute results. Whether differences be-
tween various stent designs and materials are sufficient to
impact their clinical effects remains to be demonstrated in
controlled “stent versus stent” trials. The positive results of
the few completed randomized trials have been enthusiasti-
cally applied to almost every other patient and lesion subcat-
egory. The unequivocal indications for stenting are currently
only those few that have been supported by observational and
randomized trials and are limited to very few stent types. The
definitive evidence for the use of stents for several specific
clinical indications is still lacking. As results of the many
ongoing randomized stent trials become available, the indi-
cations for stenting will have to be adapted accordingly.
Currently, there is solid evidence from observational studies
and randomized trials to support the use of coronary stents for
the following indications: (1) treatment of abrupt or threat-
ened vessel closure during angioplasty, (2) primary reduction
in restenosis in de novo focal lesions in vessels .3.0 mm in
diameter, (3) focal lesions in saphenous vein grafts, (4) totally
occluded vessels, and (5) treatment of acute MI.
Are They All Equivalent?
With the current and future plethora of intracoronary stenting
devices, the obvious question that must be answered is
whether the choice of a particular stent makes a difference
with respect to clinical outcome. Two lines of evidence, 1
experimental and the other clinical, suggest that a difference
TABLE 5. In Vivo Antisense Studies
Investigators
Experimental
Model Gene Delivery Vehicle
% Intimal
Suppression
Simons et al74 Rat c-myb Pluronic gel 84
Edelman et al75 Rat c-myb EVav 80
Azrin et al76 Pig c-myb Hydrogel catheter NR
Gunn et al77 Pig c-myb None 65
Bennet et al78 Rat c-myb Pluronic gel 53
Edelman et al75 Rat c-myb EVac 90
Shi et al79 Pig c-myb None 70
Morishita et al80 Rat cdc-2/PCNA HVJ 68
Abe et al81 Rat cdc-2 Pluronic gel 47
Abe et al81 Rat cdk-2 Pluronic gel 55
Morishita et al82 Rat cdk-2 HVJ 40
Simons et al
83
Rat PCNA Pluronic gel 80
Sirois et al84 Rat PDGD-b receptor EVac 70
EVac indicates ethylenevinylacetate; HVJ, hemagglutinating virus of Japan; and NR, not reported.
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does indeed exist between different stents.87–90 In an animal
model, it has been suggested that stent surface material and
geometric configuration may be more important than
operator-dependent variables in determining the degree of
neointimal hyperplasia and thrombosis.87 Design characteris-
tics such as hoop strength91 and metallic surface area92 have
been shown to influence neointimal formation in experimen-
tal models. The metal composition and characteristics of the
stent surface may also be important for the performance of the
implanted stent.93–102
Another factor that must be considered when assessing
stent design is the mode of delivery: self-expanding versus
balloon-expandable. The currently available self-expanding
stents are configured as a slotted tube (Radius) or as a wire
mesh (Wallstent) and are composed of either nitinol (Radius)
or stainless steel (Wallstent). Although different in configu-
ration and metal composition, they have in common a
continued expansion after deployment. The nitinol device
will continue to expand to its nominal programmed diameter,
whereas the Wallstent expands to the point at which tissue
forces overcome the radial forces of the expanding stent.103,104
It must be kept in mind, however, that excessive oversizing of
the Wallstent (.0.7 mm larger than the reference diameter)
has been shown to be a powerful predictor of subsequent
restenosis.105 Further studies are necessary to better define the
particular advantages and disadvantages of the 2 different
modes of delivery.
To resolve the issue of whether stent configuration plays a
major role in determining long-term outcome, large randomized
trials are currently under way comparing various stent designs
“head to head.” The equivalency design of these trials in simple
“BElgian NEtherlands STENT study [BENESTENT]-like”
lesions is predicated on showing similarity in safety and efficacy
between the test stent and the Palmaz-Schatz stent, which serves
as the standard with which all others are compared. These trials
were not designed to test for subtle and perhaps clinically
unimportant differences between stent designs, because an
unreasonably large sample size would be required. Three trials
have been completed. In all of these, stents were implanted in
noncomplex lesions with a length of ,25 mm in native coronary
vessels. In addition to clinical end points, angiography was
obtained in a subset of the patients, and all trials were powered
to detect a 0.2-mm difference in minimal luminal diameter at 6
to 9 months after stent implantation by quantitative coronary
arteriography. The ACS stENT Clinical Equivalence in de Novo
Lesions (ACSENT) trial included 1040 patients randomized to
either Palmaz-Schatz or Multi-Link stent implantation. Statisti-
cal equivalence in both the late clinical and angiographic (Table
6) outcomes were demonstrated for the Multi-Link and the
Palmaz-Schatz stents. Likewise, clinical and angiographic (Ta-
ble 6) equivalence between the Palmaz-Schatz stent and the
Micro Stent II was shown in the Study of AVE-Micro Stent
Ability to Limit Restenosis (SMART) trial, in which 613
patients with focal de novo or restenotic native coronary lesions
were randomized. Equivalence between the GR II and the
Palmaz-Schatz stent was not demonstrated in the GR II trial.
Differences at 6-month follow-up were seen in the 6-month
clinical outcomes of target-vessel revascularization and target-
vessel failure (composite of death, MI, and target-vessel revas-
cularization) (Figure 6). Significant differences were also seen in
the 6-month follow-up angiographic parameters of minimal
luminal diameter, percent diameter stenosis, and binary resteno-
sis rate (Table 6). The reasons for these differences are not clear
but may be due in part to a higher acute residual stenosis after
stent implantation, a higher loss index in the GR II–treated
vessels (0.76 versus 0.57; P50.007), or as a result of GR II stent
undersizing or longer stent length in the GR II group. With the
large number of stents currently available, it is questionable what
practical purpose will be served by comparing all the available
stents with the “standard” (Palmaz-Schatz) or with each other.
Also, is similar performance at 6-month follow-up angiography
in a select patient population adequate to indicate equivalency?
TABLE 6. Angiographic Follow-Up of Stent Versus Stent Trials
ACSENT SMART GR II
Palmaz-Schatz Multi-Link Palmaz-Schatz Micro Stent II Palmaz-Schatz GR II
Short-term results
No. of patients 520 520 331 330 364 364
ACC B2/C (%) 60§ 63§ 63§ 62§ 48‡ 45‡
LAD (%) 43 43 42 47 40 43
Reference diameter (mm) 2.97 2.95 2.93 2.93 3.08 3.07
Post stent stenosis (%) 10 8 8 5† 10 16†
Follow-up results
MLD (mm) 1.91 1.97 2.00 1.86 1.92 1.51*
Diameter stenosis (%) 35 32 34 37 35 50*
Binary restenosis rate 21 17 23 25 19 45
ACC B2/C indicates lesion morphology according to ACC/AHA Task Force Report, J Am Coll Cardiol. 1993;22:2033–2054; LAD, left
anterior descending coronary artery; MLD, minimal luminal diameter; and binary restenosis rate, diameter stenosis .50% at
follow-up.
*P.0.001 vs Palmaz-Schatz.
†P,0.05 vs Palmaz-Schatz.
‡Graded on site.
§Graded by angiographic core laboratory.
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Other issues that must be considered when evaluating a stent,
other than equivalency to an arbitrary standard, are ease of use,
versatility, and cost.
Custom-Designed Stents
With recent improvements in deployment techniques for
intracoronary stents and increased operator experience, le-
sions previously considered not amenable to percutaneous
treatment are now being treated with intracoronary stent
implantation. Industry has responded to the demand with the
production of myriad customized stents for very particular
applications.
Bifurcation Lesions
Several new stent designs are available that are constructed
specifically for use in bifurcation lesions. The Jostent B
(Jomed International AB) is 1 such device. The configuration
and size of the cells at 1 end of the Jostent B is similar to the
first-generation Jostent M stent, with the cells connected with
V-shaped bridges. At the other end of the stent, the cells are
larger and connected with straight bridges (Figure 7A). On
full expansion, the larger cells have a diameter of 3.5 mm,
allowing easy access to the other arm of the vessel
bifurcation.
CR Bard Inc is testing a true bifurcation stent. The Bard
Bifurcation stent is shaped like a Y and is mounted on 2
balloons (Figure 7B). The main body of the stent is a single
coil, through which the 2 balloons pass. The balloons diverge
at the crux of the Y to pass separately through the 2 arms.
Implantation into animals is currently under way, and the first
human implants are being planned.
Side Branch
Stents specifically designed for use in the treatment of lesions
at the site of significant side branches are also available.
SciMed Life Systems supplies the NIRSide, which has the
same basic design as the standard family of NIR stents;
however, the cells in the center of the stent are larger than
those at the ends. When properly positioned, the number of
obstructing struts over the entrance to the side branch is
Figure 6. Clinical outcome of GR II trial comparing GR II stent
(n5364) to Palmaz-Schatz stent (n5364) showing frequency of
death and subacute thrombosis (SAT) at 30 days and frequency
of death, target-vessel revascularization (TVR), and target-vessel
failure (TVF) (death, TVI, MI) at 9 months. Differences can be
seen in frequency of both TVF and TVR between Palmaz-Schatz
stent and GR II stent.
Figure 7. A, Photograph of Jostent B
showing larger cells at 1 extreme of
stent. B, Photograph of Bard Bifurcation
Stent, a true bifurcated device. C, Pho-
tograph of Devon Side-Arm Stent show-
ing region with omitted struts. D, Photo-
graph of Devon Ostial Stent showing
reinforced struts at 1 extreme of stent.
E, Photograph of end of a Jostent Coro-
nary Stent Graft showing expandable
PTFE material sandwiched between 2
thin-strut metal stents.
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minimized and side-branch access is facilitated. The design
concept of the Jostent S (Jomed International AB) is similar
to that of the NIRSide stent (Figure 7C).
Ostial Lesions
Devon Medical produces a stent designed exclusively for use
in ostial lesions. The base design for the stent is the
Pura-Vario A. At 1 end of the stent, however, the terminal
row of cells is slightly longer and the struts slightly thicker
(Figure 7D). This not only increases the radial force of this
portion of the stent but also increases its radiopacity, which
facilitates precise positioning.
Aneurysms or Perforations
The Jostent Coronary Stent Graft (Jomed International AB) is
a unique integration of graft material into a coronary stent.
This device was constructed with a sandwich technique
whereby an ultrathin layer of expandable PTFE, specially
developed for integration into a stent graft system, is placed
between 2 stents with reduced strut thickness (Figure 7E).
The Stent Graft is also offered coated with the Corline
Heparin Surface, which has the potential to reduce the risk of
thrombus formation after stent implantation.
A novel approach to stent customization for the treatment
of vessel rupture and aneurysms has been developed by Drs
Stefanadis and Toutouzas.106 Their approach involves passi-
vation of the stent surface through the application of a
segment of autologous vascular tissue. The technique uses a
segment of cephalic vein or ulnar artery to cover the stent.
The results of implantation of a device with a vein graft
covering only the external surface of the stent have been
reported both for elective indications106–109 and in the setting
of an acute MI.108–110 Radial artery–covered stents have also
been successfully implanted in saphenous vein bypass
grafts,111,112 as well as in both the body and ostia of native
coronary vessels.112 Further studies are necessary to clarify
the potential of this technique.
Radioactive Stents
The use of stents as platform for the delivery of radiation to
the vessel wall has been receiving considerable attention.113,114
Stent-bound radioactive sources can deliver effective doses of
radioactivity to all levels of the vessel wall. It is also believed
that radioactive stents can act by culling the smooth muscle
cell population as these cells pass through the “electron
fence” at the plane of the stent wires.115
Hehrlein and colleagues116,117 were the first to describe the
use of radioactive stents, which they implanted in nondis-
eased rabbit iliac arteries. The stainless steel stents were made
radioactive by ion bombardment in a cyclotron and emitted
both g- and b-radiation from the radionuclides 55,56,57Co, 52Mg,
and 55Fe. Stents with activities of 3.9, 17.5, and 35 mCi were
tested. At 4 weeks, exposure to the 2 higher dose levels
resulted in a significant reduction in neointimal formation,
and all treated animals exhibited a significant reduction in
proliferating cell nuclear antigen–positive cell and smooth
muscle cell counts. Vascular reendothelialization occurred
despite prolonged irradiation; however, the time to complete
endothelial cell coverage was delayed in a dose-dependent
manner.
Laird et al118 also examined the effects of a radioactive coil
stent. They first ion-implanted the nonradioactive element 31P
beneath the surface of the stent. The stents were then made
radioactive by exposure to neutron irradiation, which con-
verts a fraction of the 31P atoms to 32P, a pure b-particle
emitter. This technique results in an even distribution of 32P
within the stent, which ensures homogeneous distribution of
b-particle irradiation from the stent. This technique, however,
generates other short-lived radioisotopes. Intraluminal expo-
sure for 28 days to these radioactive stents, with an initial
activity of 0.014 mCi, caused a significant reduction in
neointimal area and percent area stenosis compared with the
effects of nonradioactive stents.
The efficacy of a relatively low-dose, pure b-emitting stent
for the inhibition of intimal hyperplasia was first demon-
strated by Hehrlein and colleagues.119 32P, produced by
neutron bombardment, was ionized and ion-implanted be-
neath the outer surface of titanium-nickel stents. 32P has
several characteristics. 32P-emitting stents with activities of 4
and 13 mCi were implanted in rabbit iliac arteries, and
histomorphometry was performed at 4 and 12 weeks.119 At 4
weeks, both groups showed significant reductions in neoin-
timal formation, whereas at 12 weeks, only the group receiv-
ing the highest radiation dose showed a significant reduction
in neointima compared with nonradioactive stents.
With a similar radioactive stent, the neointimal responses
to implantation in a porcine coronary restenosis model were
examined in stents with activities from 0.15 to 23 mCi.
Neointimal formation was seen to be reduced 28 days after
the implantation of low-activity (0.15 to 0.5 mCi) and
high-activity (3 to 23 mCi) stents, but increased neointimal
formation was observed with stents of 1-mCi initial activity.
These results highlight the complexity of the response of the
vascular wall to ionizing radiations. The stent used in this trial
has subsequently become known as the Fischell IsoStent
(IsoStent/Cordis Corp, a Johnson & Johnson Interventional
Systems Co.120 It is a stainless steel Palmaz-Schatz stent that
has been modified to be b-particle–emitting by ion implan-
tation as described above. Prompted by the encouraging
results of b-particle–emitting stents on neointimal hyperpla-
sia in animal models,117–119,121,122 a multicenter pilot study
examining the feasibility and safety of the implantation of
1-mCi Palmaz-Schatz stents has been completed, and the
larger randomized IsoStent for Restenosis Intervention Study
(IRIS) trial is under way.
Proton activation of nitinol produces the predominantly
b-emitting isotope 48V. The Act-One stent (Progressive An-
gioplasty Systems Inc), the predecessor of the Paragon stent,
has been made radioactive through proton activation and
tested in pig coronary arteries.123 Radioactive Act-One stents
with 1.5 mCi of 48V activity had no effect on lumen narrowing
or vessel histology, whereas 10-mCi 48V stents inhibited
neointimal thickening compared with nonradioactive stented
control segments. Further studies are necessary to assess the
effectiveness of radioactive nitinol stents for the prevention
of restenosis.
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Stent Coatings
The list of materials used to coat metal stents in an attempt to
reduce their inherent thrombogenicity and decrease the inci-
dence of in-stent restenosis is long and ever increasing124–142
(Table 7). A few, however, deserve special attention. Most
coatings tested are placed mainly to provide a biologically
inert barrier between the stent surface and the circulating
blood. Commercially available are the gold-coated InFlow
and NIR stents and the silicon carbide–coated Tensum and
Tenax stents. In contrast to these, immobilized-heparin sur-
face coatings have been studied as a means of providing a
biologically active exterior that interacts with the circulating
blood. Many techniques have been applied to attach heparin
to synthetic surfaces; however, the description of a process
for end-point attachment of heparin to polymer-coated sur-
faces that preserves the activity of the antithrombin binding
site made the production of heparin-coated stents feasible.143
Heparin-coated stents were shown to be effective in reducing
thrombosis in rabbit peripheral vessels135 and in porcine
coronary arteries.136,137 Three heparin-coated stents are cur-
rently available for clinical use: the Cordis/Johnson & John-
son heparin-coated Palmaz-Schatz stent, on which heparin is
end-linked to the stent surface with a patented Carmeda
coating technology; the Wiktor heparin-coated stent (Hep-
amed coating)144; and the Jostent (Corline heparin coating),
on which heparin is randomly attached. Random covalent
binding of heparin to the stent surface results in variable
exposure of antithrombin binding sites, whereas high-activity
end-point attachment, as on the Cordis/Johnson & Johnson
product, ensures that all of the anti–thrombin III binding sites
remain functionally intact. Animal studies using the high-
activity heparin-coated stents have shown that up to 80% of
the antithrombin III binding activity is lost 4 weeks after stent
implantation.145 Nevertheless, reduction in rates of stent
thrombosis in animal studies led to the evaluation of the
high-activity end-point–attached heparin-coated stents in the
BENESTENT II pilot study146 and the BENESTENT II
randomized trial.147 In the 616 patients receiving a heparin-
ized stent in these studies, there was only 1 episode of
subacute thrombosis (incidence ,0.2%).
Another commercially available coated device is the
divYsio stent (Biocompatibles Ltd), which is
phosphorylcholine-coated. Phosphorylcholine is the major
phospholipid component of biological membranes. On the
basis of promising results in vitro148 and in vivo in animal
models,149–151 it is anticipated that these coated devices will
behave as intact tissue elements, a form of biomimicry, and
result in a reduction in the incidence of subacute occlusion
and an improvement in the long-term patency rates of treated
segments. These stents are now being evaluated in clinical
trials in Europe for their ability to reduce the incidence of
subacute occlusion and improve the long-term outcome in
stented coronary segments.
Fibrin coating of intravascular stents has been proposed as
a means of passivating the stent surface and providing a
platform for the recolonization of endothelial cells.138 Fibrin-
coated Palmaz-Schatz stents were shown to be free of
thrombus and foreign body reaction when examined 8 weeks
after implantation in dog peripheral arteries.139 This was
compared with the 45% incidence of thrombosis seen with
the implantation of naked stents. More notable was the
finding of endothelialization of 96% of the surface of the
fibrin-coated stents, whereas the uncoated controls were
covered with endothelial cells over only 18% of their surface.
Similar results were seen with implantation in pig coronary
arteries. In this model, no significant foreign-body, giant-cell,
or inflammatory reaction was seen up to 1 year after stent
implantation.152
Polymeric coating of the stent in situ has also been shown
to be feasible, a technique referred to as “gel paving.”142 In a
recently reported study, the application of polyethylene-
glycol-lactide hydrogel polymers to the surface of Palmaz
stents implanted in the porcine femoral artery model has been
described.153 The applied polymer is then photopolymerized
in situ to form a short-term, semipermeable barrier. Stented
segments treated in such a manner showed less gross throm-
bosis, less microscopic platelet adherence, and enhanced
vessel patency compared with control stented segments.
Many more animal data must be collected before this type of
technology can be considered for clinical application.
As a result of their long residence times, attention has
become focused on endovascular stents as a reservoir for
prolonged local drug administration for the prevention of
restenosis. This can be done by coating metallic stents with
controlled-release matrices or incorporating a pharmacologi-
cally active compound into a polymeric stent or a polymer-
metal composite stent.
Drug-polymer composites are referred to as monolithic
matrices. When nondegradable matrices are used, drugs are
delivered through sustained release by way of particle disso-
lution and diffusion through the cavitating network of the
matrix. Extended drug release is possible through this ap-
proach, with formulations with release duration from hours to
decades having been reported. Biodegradable polymer sys-
tems have also been used to formulate drug-delivery matrices.
Biodegradable polymer matrices provide sustained delivery
of pharmacological agents both by drug dissolution and by
matrix degradation in vivo, leading to release of entrapped
agents. The coating of a pharmaceutical stent with a biode-
gradable polymer also offers the attractive possibility that the
drug-polymer system could disappear after a desired period
of drug release.
Several candidate drugs for stent coatings have been
considered. Undergoing clinical assessment is an InFlow
TABLE 7. Coating Material Considered for Use With Metal
Intracoronary Stents
Synthetic Substances Naturally Occurring Substances
Polyurethane113–115 Collagen/laminin121
Segmented polyurethaneurea/heparin116 Heparin122–125
Poly-L-lactic acid117 Fibrin126
Cellulose ester118 Phosphorylcholine112
Polyethylene glycol119 AZ1 adsorbed to cellulose127,128
Polyphosphate ester120 AZ1/UK adsorbed to cellulose129,130
AZ1 indicates monoclonal antibody directed against rabbit platelet integrin
aIIbb3; AZ1/UK, monoclonal antibody directed against rabbit platelet integrin
aIIbb3/urokinase conjugate.
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stent (InFlow Dynamics AG) coated with a polylactic acid
carrier containing 5% polyethylene-glycol-hirudin and 1%
prostaglandin I2 analog (Iloprost). In vitro analysis demon-
strated favorable degradation properties of the carrier and
time-release characteristics of the incorporated antithrom-
botic and platelet-inhibiting drugs.154 Analysis of the hirudin-
and Iloprost-eluting stents tested during stasis in a human
shunt model demonstrated a significant effect on both platelet
activation and blood coagulation,155 and when implanted in
sheep coronary arteries, they have been shown to exhibit a
favorable effect on neointimal formation.156 Another carrier/
active agent system that appears promising is a cellulose
polymer with passively adsorbed glycoprotein IIb/IIIa recep-
tor antibody.140,141,157 Active compound elutes from the stents
in an exponential manner, with 48% of the bound agent eluted
at 12 days when studied in vitro.158 When investigated in a
rabbit iliac artery model, antibody to glycoprotein IIb/IIIa
eluted from cellulose-polymer–coated stents significantly
reduced platelet aggregation in the stent microenvironment,
reduced thrombus formation, improved blood flow and arte-
rial patency rates, and inhibited cyclic blood flow variation.157
The use of gene therapy in conjunction with a pharmaceu-
tical delivery stent could involve the transfer of a desired gene
from the stent coating to the cells of the arterial wall. This
should result in the expression and synthesis of a desirable
product by the cells of the arterial wall. This approach would
involve the incorporation of DNA or a viral vector into a
polymeric matrix system under conditions that would facili-
tate cellular uptake and translation of the DNA. Another
important possible strategy for a pharmaceutical stent ap-
proach might involve the incorporation of antisense oligonu-
cleotides into an appropriate polymeric matrix.159,160
Interest in the development of a suitable biodegradable
stent with pharmacologically active agents incorporated into
the polymeric matrix, once a very active area of research, has
waned considerably. To be effective, a drug-releasing biode-
gradable stent must be biocompatible, it must not cause an
inflammatory reaction, and the breakdown products must be
nontoxic. One such biodegradable device, however, that
warrants mention is the Duke Biodegradable Stent, which is
made from a special form of poly-L-lactide capable of
incorporating pharmacologically active agents.161 Both self-
expanding and balloon-expandable versions of the Duke stent
have been designed and tested in animals,162 with promising
results.
The seeding of intravascular stents with endothelial cells to
passivate the stent surface has been an area of ongoing
research for .9 years. Both self-expanding163 and balloon-
expandable164 stents have been successfully seeded with
endothelial cells and have been shown to retain a significant
number of viable cells after deployment in vitro.163–165 Using
autologous endothelial cells derived from sheep saphenous
veins, a group at the National Heart, Lung, and Blood
Institute (NHLBI) has successfully seeded metallic stents and
implanted the stents into the femoral arteries of the donor
animals.166 The transplanted endothelial cells could be de-
tected in 6 of 9 animals treated in this manner 10 days after
stent implantation. Scott and colleagues167 also were success-
ful in identifying endothelial cells on seeded stents 3 hours
after intracoronary implantation in pigs. These investigators
used immortalized human microvascular cells that retain the
phenotypic characteristics of endothelial cells after .50
passages.168 The relevance of continued investment into the
development of endothelium-covered stents may lie in the
future possibility of seeding the stents with genetically
modified endothelial cells capable of producing compounds
for the treatment of restenosis.
Future Advances
Despite the phenomenal pace of stent design technology, the
incidence of stent restenosis remains unacceptably high. To
address this problem, intense investigation into new stent
coatings continues, with new biocompatible and drug-eluting
polymers being developed for application to the metal stent
scaffold. As novel biocompatible drug delivery stent coatings
are developed, pharmacological compounds that failed to
prevent restenosis when administered systemically and those
with significant systemic toxicity are now being reexamined.
The new drug-eluting stents also provide a unique platform
for the administration of proteinaceous compounds, antisense
oligonucleotides, and DNA that cannot be given systemically.
In addition, metal stents provide a convenient means for the
application of brachytherapy by use of ionizing radiation.
Although initial clinical results seem promising, issues of
correct dosimetry and the long-term effects of cytotoxic
therapies on the arterial wall have arisen. Despite recent
significant strides in stent design technology, it is apparent
that much has yet to be learned and further advances are
necessary to improve the long-term outcome of patients
treated with intravascular stents.
Angiogenesis and
Transmyocardial Revascularization
Perhaps the most intriguing and exciting frontier in interven-
tional cardiology is the ability to induce the growth of new
blood vessels, a radically different therapeutic orientation
compared with bypassing or deblocking diseased arteries.
Several approaches have undergone pilot studies and have
entered clinical trials involving either local angiogenic
polypeptide growth factor administration, transfection of
angiogenic genes, or the development of small channels in the
endocardium to promote the passage of blood from the left
ventricular cavity into the myocardium. The principal mech-
anism of improved myocardial blood flow for the latter
approach, known as transmyocardial revascularization, is
most likely related to stimulating angiogenesis, because the
holes created by the laser (or other means) become fibrotic
and occlude within weeks after the procedure.168–170
Therapeutic angiogenesis is undergoing intensive early
clinical investigation. Isner et al171,172 transfected the periph-
eral arteries with the cDNA for VEGF165 via a hydrogel-
coated balloon catheter. This was successful in a few patients
for improving peripheral arterial ischemia and served as proof
of concept; then the same group initiated intramuscular
injection of the VEGF165 naked human plasmid cDNA in 9
patients (10 ischemic limbs). In this initial series of intramus-
cular (rather than intra-arterial) injection of an angiogenic
gene, 8 of 10 limbs had improved blood flow demonstrated
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by MRI, and there was an overall 30% increase in the
ankle-brachial index, a key measure of ameliorated limb
blood supply. Patients were excluded for any known malig-
nancy, diabetic retinopathy, or other conditions that might be
associated with untoward sequelae from “inappropriate”
angiogenesis.
More recently, the initial forays into coronary angiogenesis
have been reported. Schumacher et al,173 from Freiburg,
Germany, published the results of a randomized trial of 40
patients who had intramyocardial injection of acidic fibro-
blast growth factor (FGF-1) into the distal anterior wall at the
time of internal mammary artery bypass graft surgery. Within
12 weeks, the 20 patients randomized to active FGF-1 had
digital angiographic evidence of neovascularization.173 Dur-
ing 3 years of follow-up, the ejection fraction improved from
50.3% to 63.8% in the treated group compared with 51.5% to
59.4% in the control (heat-inactivated FGF-1) group. No
accelerated atherosclerosis or other untoward events were
found.
In a parallel clinical investigation, intramyocardial injec-
tion of the gene for VEGF121 was initiated using an adenoviral
vector at the time of bypass surgery.174 Like the clinical
studies of Shumacher and colleagues, there was evidence
from this preclinical porcine model of Mack et al175 of
extensive neovascularization at 4 weeks after VEGF
transfection.
Henry and colleagues176 presented their findings on intra-
coronary VEGF administration in a small dose-finding pilot
trial of 15 patients, which showed marked improvement in
perfusion in 7 patients (47%) by thallium scintigraphy and
improved collateralization in 5 of 7 patients who underwent
follow-up angiography. A larger follow-up study that com-
bines intracoronary and subsequent intravenous VEGF has
just been initiated. Laham and associates177 used epicardial
microcapsules with basic fibroblast growth factor in 8 pa-
tients at the time of bypass surgery, 4 of whom had enhanced
perfusion by nuclear scans and MRI.
It was not fully anticipated that a single injection of either
angiogenic protein or gene would produce prolonged neovas-
cularization. This raises the question as to whether there is
upregulation of angiogenic factors or their receptors once the
stimulus is initiated.178 The process of new blood vessel
formation is such a complex and well-orchestrated series of
events, requiring a multitude of growth factors and regulatory
proteins, that it is probably naive to think that a 1-time
application of a single growth factor will yield optimal
angiogenesis. The gene transfer approach may be preferred
over the protein with regard to potential for durability, but
with the adenoviral vector, issues including gene regulation
over time and the potential for induction of a host inflamma-
tory response are poorly understood. The naked cDNA
plasmid strategy, applied for the peripheral arterial insuffi-
ciency indication, is fraught with low efficiency of transfer
and probably more transient gene expression.
Although the angiogenesis can be demonstrated by imag-
ing modalities, it is uncertain whether it will lead to normal-
ization of perfusion or complete mitigation of provokable
ischemia. It remains to be seen whether the collateral supply
will be enhanced for long-term follow-up, but the functional
data provided by Schumacher’s group are, at the very least,
encouraging. Still, the unknown effects of accelerating ath-
erosclerosis or facilitation of a latent malignancy need to be
carefully assessed. Notwithstanding these concerns, large-
scale clinical investigation for coronary angiogenesis with
either the protein or gene for specific growth factors is
warranted.
Substantial clinical pilot studies of transluminal myocar-
dial revascularization (TMR) have suggested the potential for
relief of angina.179–185 Three clinical trials have been com-
pleted with TMR performed at the time of open-heart surgery.
With the CO2 laser, 198 patients were randomized to TMR or
initial medical therapy.186 Holmium laser was also the subject
of a randomized trial that enrolled 162 patients.187 The results
of these 2 trials are remarkably concordant with reduction of
angina, improvement of functional status, and in select
patients with ancillary nuclear imaging, improved perfusion.
As summarized in Figure 8, these salutary effects were also
associated with less need for repeat hospitalization and less
antianginal medication. For example, in the study by Allen et
al,187 the need for cardiac hospitalization at 3 months was
reduced from 43% in medically managed patients to 20% in
the group treated with TMR. Thus, it appears that TMR is
effective for reducing angina, but the mechanism is not fully
elucidated. Because the holes occlude fairly quickly, over just
a few weeks in postmortem studies and experimental models,
the most likely explanation for the benefit is angiogenesis.168–
170,188 However, neuronal dysfunction induced by the laser has
been raised as a plausible explanation for some of the
antianginal effect based on elegant experimental modeling
that focused on reflexes to systemic hypotension with brady-
kinin applied directly to the epicardium after TMR.189 Recent
mechanistic studies have verified improvement in dobuta-
mine-induced angina threshold, myocardial blood flow by
PET, and even on indices of ventricular repolarization.190–192
With regard to safety, there were some initial concerns
regarding a high operative mortality in these series (in the 8%
to 10% range), but more recent experience suggests that this
may have been attributable to patient selection or an obliga-
tory operator learning curve.
The encouraging results in the initial surgical trials have
led to clinical investigation with the use of holmium or
Figure 8. Incidence of class I or II angina among patients ran-
domized in 2 trials of transmyocardial revascularization (TMR) vs
medical therapy (Med) (References 74 and 75). All patients had
class 3 or 4 angina at time of enrollment.
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excimer laser via the percutaneous approach.193,194 To date, no
randomized trial data are available, but pilot studies demon-
strate feasibility and apparent safety in the first few hundred
patients treated. Clearly, the ability to direct the laser to the
ischemic myocardial bed is lessened with the percutaneous
approach, but new catheter-based sensor systems that are
nonfluoroscopic and use electroanatomic mapping are being
investigated to improve on the precision of where the holes
are applied.195,196 Because the dominant mechanism may
relate to stimulation of angiogenesis, it is not clear that
precision is vital. The damage to the myocardium that is
anticipated in the form of non–ST-elevation MI and its
long-term effects has not been amply studied. A percutaneous
strategy has obvious advantages, because it will allow more
ready application to patients who are truly inoperable or can
be used as an adjunct in patients with a chronic total occlusion
that is not amenable to a routine epicardial strategy. Never-
theless, TMR will need considerable study and comparison
with pharmacological or genetic forms of angiogenesis. Even
the concept of injected angiogenic factors at the time the
holes are created has been subjected to experimental study
and, if shown clinically to be synergistic, may someday prove
to be a useful combined strategy.197
Another highly provocative strategy is a tissue-engineered
blood vessel. L’Heureux and associates,198 in Quebec, have
demonstrated the feasibility of cloning new arteries via
cultured human smooth muscle cells, endothelial cells, and
fibroblasts. Although this seems futuristic, it is possible that
larger, bioengineered vessels cloned from patients who have
significant ischemia may be a viable alternative in the next
millennium to the conventional epicardial or emerging angio-
genesis interventions of today.
Overall Perspective
The field of interventional cardiology is poised to go through
significant further development. By the start of the 2000s,
improved platelet coverage will be routine in all patients
undergoing procedures, and oral therapies for more extended
periods during follow-up will be more thoroughly investi-
gated. It would not be at all surprising if angiogenesis
therapy, be it by intracoronary, intramyocardial (at the time of
surgery), or transmyocardial laser revascularization, became
an important adjunctive means of achieving improved myo-
cardial blood flow. Restenosis therapies will undoubtedly
blossom beyond the initial application of radiation for in-stent
restenosis, ideally taking advantage of the increased under-
standing that we now have of genetic control of cell prolif-
eration and matrix production. Although stents are already
being used in .60% of patients at the time of interventional
procedures, their use will also increase further with improved
designs, coatings, and the newfound ability to use the stent as
an effective drug delivery station.
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